Zocin-100 Suspension 60ml

Side Effects of Zocin-100 Suspension 60ml

Physical dependence; sedation, dizziness, euphoria, lightheadedness, alterations of mood; respiratory depression; visual hallucinations, disorientation, confusion; hypertension, tachycardia, circulatory depression; shock; hypotension; nausea, vomiting, constipation; seizures, diaphoresis; rash; blood dyscrasias; local tissue damages (SC), muscle fibrosis (IM). Potentially Fatal: Respiratory depression, hypotension, circulatory failure, deepening coma, convulsions.

Drug Interactions

Depressant affects potentiated by alcohol, CNS depressants; concurrent use with fluoxetine may lead to diaphoresis, ataxia flushing and tremor associated with serotonin syndrome.

Contraindications

Head injury; narcotic dependence; respiratory depression; raised intracranial pressure; MI; heart failure; arterial or pulmonary hypertension; porphyria; pregnancy (prolonged use or high doses at term).

Mechanism of Action

Pentazocine is a benzomorphan derivative with mixed opioid agonist and antagonist actions. It alters perception of and response to pain and produces generalised CNS depression by binding to opiate receptors in the CNS and acting as a partial agonist/antagonist. Onset: Oral, IM, SC: 15-30 minutes; IV 2-3 minutes. Duration: Oral: 4-5 hr; parenteral: 2-3 hr. Absorption: Absorbed from the GI tract (oral), through the muscles (IM); peak plasma concentrations after 1-3 hr (oral), 15 min-1 hr (IM). Oral bioavailability: approx 20% (60-70% in cirrhosis). Distribution: Crosses the placenta. Protein-binding: 60% Metabolism: Hepatic; via oxidative and glucuronide conjugation pathways; extensive 1st pass. Excretion: Elimination half life: 2-3 hr; prolonged in hepatic impairment; excretion via urine (small amounts as unchanged drug).

Special Precautions

May precipitate withdrawal in narcotic addicts. Impaired respiratory, renal and hepatic function; morbidly obese patients; thyroid dysfunction; prostatic hyperplasia or urinary stricture; biliary tract impairment; adrenal insufficiency (including Addison's disease); abdominal conditions. Elderly or debilitated patients; seizure-prone patients; children and infants (safety and efficacy not established in <1 yr); lactation. May impair ability to drive or operate machinery. Administer IM rather than SC (when frequent inj are needed) and inj sites should be varied.

How to Use

Take orally with food and water, as directed by your physician.

How to Store

Keep in a cool, dry place away from sunlight and moisture.

Safety Concerns

• Alcohol: Avoid during treatment.
• Breastfeeding: Not recommended.
• Pregnancy: Contraindicated.
• Liver/Kidney: Use with caution.

Content Disclaimer

This content is for educational purposes only. Please consult your doctor before use.